Clinical Trial

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.
Protocol Amendment History 1 change
notable Trial sites expanded: 12 -> 15 locations 2026-06-04
Trial Details
NCT Number NCT07217860
Lead Sponsor Xenon Pharmaceuticals Inc.
Conditions Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Enrollment 400 participants
Start Date 2025-10-30
Primary Completion 2029-06 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-03